Exelixix

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
PM Live
Wed, 02/10/21 - 12:09 am
Bristol Myers Squibb
Exelixix
Opdivo
Cabometyx
kidney cancer
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Yahoo
Sun, 06/5/16 - 11:59 am
Exelixix
Ipsen
clinical trials
advanced renal cell carcinoma
Cabometyx
ASCO 2016
Exelixis Licenses PI3K-Delta Program to Merck
Yahoo
Wed, 12/21/11 - 12:55 pm
Merck
Exelixix
P13K-Delta
XL-499